DSpace Repository

Multiantigen print immunoassay (MAPIA) for the diagnosis of neurocysticercosis: a single-center diagnostic optimization and accuracy study in Lima, Peru.

Show simple item record

dc.contributor.author Toribio Salazar, Luz Milagros
dc.contributor.author Guzman, C.
dc.contributor.author Noazin, S.
dc.contributor.author Zimic Sheen, Alen Mirko
dc.contributor.author Zimic-Peralta, Mirko Juan
dc.contributor.author Gonzales, I.
dc.contributor.author Saavedra, H.
dc.contributor.author Pretell, E. J.
dc.contributor.author Bustos Palomino, Javier Arturo
dc.contributor.author Handali, S.
dc.contributor.author García Lescano, Héctor Hugo
dc.date.accessioned 2023-12-05T17:48:02Z
dc.date.available 2023-12-05T17:48:02Z
dc.date.issued 2023
dc.identifier.uri https://hdl.handle.net/20.500.12866/14651
dc.description.abstract Neurocysticercosis (NCC) is the most common helminthic infection of the human central nervous system. The antibody detection assay of choice is the enzyme-linked immunoelectrotransfer blot assay using lentil-lectin purified parasite antigens (LLGP-EITB, Western blot), an immunoassay with exceptional performance in clinical samples. However, its use is mainly restricted to a few research laboratories because the assay is labor-intensive and requires sophisticated equipment, expertise, and large amounts of parasite material for preparation of reagents. We report a new immunoprint assay (MAPIA) that overcomes most of these barriers. We initially compared the performance of five different antigen combinations in a subset of defined samples in the MAPIA format. After selecting the best-performing assay format (a combination of rGP50 + rT24H + sTs14 antigens), 148 archived serum samples were tested, including 40 from individuals with parenchymal NCC, 40 with subarachnoid NCC, and 68 healthy controls with no evidence of neurologic disease. MAPIA using three antigens (rGP50 + rT24H + sTs14) was highly sensitive and specific for detecting antibodies in NCC. It detected 39 out of 40 (97.5%) parenchymal NCC cases and 40/40 (100%) subarachnoid cases and was negative in 67 out of 68 (98.53%) negative samples. MAPIA using three recombinant and synthetic antigens is a simple and economical tool with a performance equivalent to the LLGP-EITB assay for the detection of specific antibodies to NCC. The MAPIA overcomes existing barriers to adoption of the EITG LLGP and is a candidate for worldwide use. en_US
dc.language.iso eng
dc.publisher American Society for Microbiology
dc.relation.ispartofseries Journal of Clinical Microbiology
dc.rights info:eu-repo/semantics/restrictedAccess
dc.rights.uri https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es
dc.subject Multiantigen print immunoassay en_US
dc.subject MAPIA en_US
dc.subject neurocysticercosis en_US
dc.subject accuracy study en_US
dc.subject Peru en_US
dc.subject.mesh Inmunoensayo
dc.subject.mesh Neurocisticercosis
dc.subject.mesh Perú
dc.subject.mesh Exactitud de los Datos
dc.title Multiantigen print immunoassay (MAPIA) for the diagnosis of neurocysticercosis: a single-center diagnostic optimization and accuracy study in Lima, Peru. en_US
dc.type info:eu-repo/semantics/article
dc.identifier.doi https://doi.org/10.1128/jcm.00760-23
dc.relation.issn 1098-660X


Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

info:eu-repo/semantics/restrictedAccess Except where otherwise noted, this item's license is described as info:eu-repo/semantics/restrictedAccess

Search DSpace


Browse

My Account

Statistics